viDA Therapeutics, Inc. (viDA), is advancing first-in-class drugs based on inhibitors of the extracellular serine protease, Granzyme B (GzmB), to treat autoimmune and chronic inflammatory diseases. The company is focused on advancing their lead candidate into the clinic for the treatment of the orphan disease, Discoid Lupus Erythematosus (DLE), a chronic inflammatory autoimmune skin disorder. Based on preclinical studies with our topically formulated lead compound VTI-1002, the company is planning to file an Investigational New Drug (IND) application with the FDA within the next 12 months.
viDA IN THE NEWS
Scientists find genetic wrinkle to block sun-induced skin aging.
The secret to great skin.